source
- Odyssey raises more than $300M as biotech goes publicOdyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The bio…Endpoints · 2mo ago↗ source
- Fraudulent citations, blamed on AI hallucinations, are becoming more common in research papers“Fabricated” citations that do not reference real academic papers are spreading in the literature, polluting the public record of science, a new study foundSTAT · 2mo ago↗ source
- Astellas touts data from early test of stem cell-derived eye therapyAstellas reported promising results with its stem cell-derived therapy in an age-related eye disease, though data in a handful of high-dose patients in the early-stage study raised questions. The e…